126.61
+3.11
(2.52%)
Real-time:
11:23AM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 123.68 - 128.35 |
| 52 week | 58.53 - 131.82 |
| Open | 124.11 |
| Vol / Avg. | 2.08M/3.33M |
| Mkt cap | 52.81B |
| P/E | 38.42 |
| Div/yield | - |
| EPS | 3.30 |
| Shares | 417.12M |
| Beta | 0.67 |
| Inst. own | 84% |
Events
Jun 12, 2013
Celgene Corp. Annual Shareholder Meeting
- 1:00PM EDT -
May 30, 2013
Celgene Corp. at Sanford C Bernstein Strategic Decisions Conference
- 9:00AM EDT -
May 22, 2013
Celgene Corp. at UBS Global Healthcare Conference
- 11:30AM EDT -
May 16, 2013
Celgene Corp. at Bank of America Merrill Lynch Health Care Conference -
May 9, 2013
Celgene Corp. at Robert W Baird and Co Growth Stock Conference -
May 6, 2013
Celgene Corp. Analyst Meeting -
Apr 25, 2013
Q1 2013 Celgene Corp. Earnings Conference Call -
Apr 23, 2013
Q1 2013 Celgene Corp. Earnings Release
Mar 14, 2013
Celgene Corp. at Barclays Healthcare Conference -
Mar 5, 2013
Celgene Corp. at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 26.28% | 26.44% |
| Operating margin | 31.67% | 31.71% |
| EBITD margin | - | 39.93% |
| Return on average assets | 13.32% | 13.40% |
| Return on average equity | 27.45% | 25.99% |
| Employees | 4,700 | - |
| Carbon Disclosure Rating | - | 54/100 |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Transcripts - SeekingAlpha
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
Officers and directors
| Robert J. Hugin | Chairman of the Board, Chief Executive Officer | |
| Jacqualyn A. Fouse Ph.D. | Chief Financial Officer, Executive Vice President | |
| Perry A. Karsen | Chief Operating Officer, Executive Vice President | |
| Mark J. Alles | Executive Vice President, Chief Commercial Officer | |
| Thomas O. Daniel M.D. | Executive Vice President, President - Research and Early Development | |
| Michael D. Casey | Lead Independent Director | |
| Richard W. Barker OBE | Independent Director | |
| Carrie S. Cox | Independent Director | |
| Rodman L. Drake | Independent Director | |
| Michael A. Friedman M.D. | Independent Director |